Host with the most: Targeting host cells instead of pathogens to fight infectious disease

In a recent news article published in Nature Medicine by Amanda B. Keener, the background of Atriva's antiviral MEK inhibitor technology was highlighted. Three of our founders were interviewed in this article and shared their views on past and future developments in influenza treatment:

Nature Medicine 23, 528–531 doi:10.1038/nm0517-528

Atriva receives seed financing to develop its next generation influenza therapeutic

The next generation of Antiviral Therapies: Led by Stichting Participatie Atriva together with High-Tech Gründerfonds (HTGF), Atriva Therapeutics GmbH has received seed financing from Dutch and German private investors to advance Atriva’s antiviral MEK-Inhibitors (Mitogen-activated protein kinase kinase inhibitor) against Influenza into the clinical development stage.


Atriva Therapeutics Announces Upcoming US Patent Issuance for MEK Treatment against Viral Diseases

Tübingen, Germany, November 04, 2016 -- Atriva Therapeutics GmbH announces that the USPTO issued the Notice of allowance meaning that grant of one of its core patents: “MEK Inhibitors in the treatment of virus diseases” (US Application 14/434,328) is intended.


Atriva Therapeutics completes transfer of Co-Infection Patent

June 30th, 2016, Tübingen, Germany

Atriva Therapeutics GmbH announces the acquisition of the co-infection patent (Application Nr: PCT/IB2015/053644) from the University of Muenster, Germany.


ATRIVA Therapeutics Gewinner des S4L Venture Cups 2016

In Berlin wurden Anfang März die Gewinner der Konzeptphase des Science4Life Venture Cups gekürt.

Read more ...